1 AZD 2014 , an inhibitor of mTORC 1 and mTORC 2 , is highly effective in ER + breast cancer when administered using intermittent or continuous schedules

نویسندگان

  • Sylvie M. Guichard
  • Jon Curwen
  • Teeru Bihani
  • Celina M. D’Cruz
  • James W.T. Yates
  • Michael Grondine
  • Zoe Howard
  • Barry Davies
  • Graham Bigley
  • Teresa Klinowska
  • Kurt G. Pike
  • Martin Pass
  • Christine M. Chresta
  • Urszula Polanska
  • Robert McEwen
  • Oona Delpuech
  • Stephen Green
  • Sabina C. Cosulich
چکیده

AZD2014, an inhibitor of mTORC1 and mTORC2, is highly effective in ER+ breast cancer when administered using intermittent or continuous schedules. Sylvie M. Guichard, Jon Curwen, Teeru Bihani, Celina M. D’Cruz, James W.T. Yates, Michael Grondine, Zoe Howard, Barry Davies, Graham Bigley, Teresa Klinowska, Kurt G. Pike, Martin Pass, Christine M. Chresta, Urszula Polanska, Robert McEwen, Oona Delpuech, Stephen Green, and Sabina C. Cosulich *these authors contributed equally to the work

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

A Role for MEK-Interacting Protein 1 in Hormone Responsiveness of ER Positive Breast Cancer Cells PRINCIPAL INVESTIGATOR:

MEK Partner 1 (MP1 or MAPKSP1) is a scaffold protein that has been reported to function in multiple signaling pathways, including the ERK, PAK and mTORC pathways. Several of these pathways influence the biology of breast cancer, but MP1’s functional significance in breast cancer cells has not been investigated. In this report, we demonstrate a requirement for MP1 expression in estrogen receptor...

متن کامل

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.

mTOR is an atypical serine threonine kinase involved in regulating major cellular functions, such as nutrients sensing, growth, and proliferation. mTOR is part of the multiprotein complexes mTORC1 and mTORC2, which have been shown to play critical yet functionally distinct roles in the regulation of cellular processes. Current clinical mTOR inhibitors only inhibit the mTORC1 complex and are der...

متن کامل

Fomepizole as a First-line Treatment of Patients with Methanol Poisoning

Methanol is responsible for a life-threatening poisoning. Fomepizole, a potent alcohol dehydrogenase inhibitor, is an efficient and safe antidote that prevents or reduces toxic methanol metabolism. Although no study has compared its efficacy with ethanol, fomepizole is recommended as a first-line antidote. Treatment should be started as soon as possible, based on history and initial findings in...

متن کامل

Small Molecule Therapeutics AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER Breast Cancer When Administered Using Intermittent or Continuous Schedules

mTOR is an atypical serine threonine kinase involved in regulating major cellular functions, such as nutrients sensing, growth, and proliferation. mTOR is part of the multiprotein complexes mTORC1 and mTORC2, which have been shown to play critical yet functionally distinct roles in the regulation of cellular processes. Current clinical mTOR inhibitors only inhibit the mTORC1 complex and are der...

متن کامل

PAM pathway and its relevance in breast cancer

The phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) (PAM) pathway is frequently activated in breast cancer, with PIK3CA being the most commonly mutated gene of significance in estrogen receptor (ER) positive breast cancer. Activation of the pathway has been associated with resistance to endocrine therapy, human epidermal growth factor receptor 2 (HER2)-directed therapy...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2015